Yes. MICHAEL J. ARNOLD, MD, FAAFP, AND PATRICK G. O'MALLEY, MD, MPH, FACP, Uniformed Services University of the Health Sciences, Bethesda, Maryland, JOHN R. DOWNS, MD, FACP, University of Texas Long School of Medicine, San Antonio, Texas, Related practice guideline: Dyslipidemia Management for Cardiovascular Disease Prevention: Guidelines from the VA/DoD, Related letter to the Editor: USPSTF Recommendations for the Management of Dyslipidemia for Cardiovascular Risk Reduction. Proc Jpn Acad Ser B Phys Biol Sci. Low-density lipoprotein cholesterol-lowering therapy in the primary C recommendation. They do not represent the views of the Agency for Healthcare Research and Quality, the U.S. Department of Health and Human Services, or the U.S. Public Health Service. Keep from freezing. include protected health information. Statin alternative bempedoic acid cuts cholesterol, heart attack risk Click here for an email preview. It may help to increase high-density lipoprotein (HDL), or good. Twenty two patients had their statin's dosage decreased to half while eighty one patients had their initial statin's dosage maintained after target LDL-C (less than 100mg/dL) level achieved. Do not use more of it, do not use it more often, or do not use it for a longer time than your doctor ordered. 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). doi:10.2183/pjab.86.484, Mills EJ, Wu P, Chong G. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). After starting medication based on treatment intensity, further measurement of cholesterol is unnecessary. Because the Pooled Cohort Equations lack precision, the risk estimation tool should be used as a starting point to discuss with patients their desire for lifelong statin therapy. privacy practices. In June 2020, the third iteration of the VA/DoD guidelines on managing dyslipidemia was published1 (see Figure 1 in the related practice guideline in this issue of American Family Physician). Key Recommendations on Managing Dyslipidemia for Cardiovascular - AAFP The conversation should include major risk factors such as cigarette smoking, elevated blood pressure, LDL-C levels, A1C (if indicated), and calculated 10-year risk of ASCVD; the presence of risk-enhancing factors; the potential benefits of lifestyle and statin therapies; the potential for adverse effects and drugdrug interactions; cost of therapy; and patient preferences and values in shared decision-making. When an initial nonfasting lipid profile reveals a triglyceride level of 400 mg per dL (4.5 mmol per L) or greater, a repeat lipid profile should be obtained to assess fasting triglyceride and baseline LDL-C levels in adults 20 years and older. Patients who place a higher value on the potential benefits than on the potential harms and inconvenience of taking a daily medication may choose to initiate statin use for reduction of CVD risk. Using previous cholesterol values to calculate risk every two to five years offers the opportunity to decrease unnecessary testing. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Statin drugs are among the most commonly prescribed medications in the U.S. with annual sales of over $18 billion, according to research from the Northwestern University Feinberg School of Medicine in Chicago. Thus, clinicians should discuss with patients the potential risk of having a CVD event and the expected benefits and harms of statin use. The American Heart Association and American College of Cardiology also reflect this update in their 2018 guidelines. A historical perspective on the discovery of statins. Copyright: Merative US L.P. 1973, 2023. 2006 Jun;28(6):933-42. doi: 10.1016/j.clinthera.2006.06.004. The determination is made based on . https://doi.org/10.1016/j.jacc.2018.11.003, https://www.aafp.org/patient-care/clinical-recommendations/all/cholesterol.html. The USPSTF found inadequate evidence to conclude whether initiating statin use in adults 76 years and older who are not already taking a statin is beneficial in reducing the incidence of CVD events and mortality. How quickly can niacin help to lower cholesterol? - Medical News Today information submitted for this request. Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Also, this medicine works best if there is a constant amount in the blood. See permissionsforcopyrightquestions and/or permission requests. Statins are used to lower the bad cholesterol (LDL cholesterol) levels in your blood. Cholestyramine light: The starting dose is 1 pouch (4 grams) or 1 level scoopful (4 grams) taken by mouth, once or twice per day. Risk 20% (high risk). Rather, it suggests that the benefits may be smaller and that clinical judgment needs to be made on a case-by-case basis. Medically reviewed by Drugs.com. Children younger than 7 years of ageUse and dose must be determined by your doctor. For the purposes of this recommendation, dyslipidemia is defined as an LDL-C level greater than 130 mg/dL or a high-density lipoprotein cholesterol (HDL-C) level less than 40 mg/dL (to convert HDL-C values to mmol/L, multiply by 0.0259). The USPSTF recommends using the ACC/AHA Pooled Cohort Equations to calculate 10-year risk of CVD events.13 In 2013, the ACC/AHA released the Pooled Cohort Equations with the publication of new statin therapy guidelines.1 The calculator derived from these equations takes into account age, sex, race, cholesterol levels, systolic blood pressure level, antihypertension treatment, presence of diabetes, and smoking status as risk factors in the prediction model and focuses on hard clinical outcomes (heart attack and death from coronary heart disease; ischemic stroke and stroke-related death) as the outcomes of interest. A collection of USPSTF recommendation statements published in AFP is available at https://www.aafp.org/afp/uspstf. Niacin is a B vitamin that can improve all lipoprotein levels. other information we have about you. A very unhealthy diet. Treatment with low- to moderate-dose statins is recommended for adults 40 to 75 who haven't had a heart attack or stroke but are at risk of one. How statins work. All Rights Reserved. participants who received a daily dose of bempedoic acid experienced a 23.2% reduction in LDL cholesterol and a 22.7% . After one month, your doctor may increase your dosage based on . Statins help lower low-density lipoprotein (LDL) cholesterol, also known as "bad" cholesterol, in the blood. Clinicians may choose to offer a low- to moderate-dose statin to certain adults without a history of CVD when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they. This risk calculator has been the source of some controversy, as several investigators not involved with its development have found that it overestimates risk when applied to more contemporary U.S. cohorts, especially those at the lower end of the risk spectrum.14 Although other risk prediction tools are available, they address varying populations, risk factors, and outcomes and have their own limitations. Statins are prescription medications that can lower your cholesterol levels. 2016;316(19):1997. doi:10.1001/jama.2016.15450, Taylor F, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. By Mayo Clinic Staff Statins are drugs that can lower your cholesterol. Brand name: Lipitor. The USPSTF found inadequate evidence on the harms of statin use for the prevention of CVD events in adults 76 years and older without a history of heart attack or stroke. Methods We evaluated healthcare records of 934,332 subjects from North-Italy, including subjects with available lipid profile and being on statin treatments up to December . Can I Drink Alcohol While Taking Lipitor and Other Statins? Would you like email updates of new search results? Jama. It found insufficient evidence that screening for dyslipidemia before age 40 years has an effect on either short- or longer-term cardiovascular outcomes.19,20 The USPSTF found no studies that evaluated the effects of screening vs. no screening, treatment vs. no treatment, or delayed vs. earlier treatment in adults in this age group. Use of low- or moderate-dose statins was associated with a reduced risk of all-cause mortality (pooled risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]), cardiovascular mortality (RR, 0.69 [95% CI, 0.54 to 0.88]), ischemic stroke (RR, 0.71 [95% CI, 0.62 to 0.82]), heart attack (RR, 0.64 [95% CI, 0.57 to 0.71]), and a composite cardiovascular outcome (RR, 0.70 [95% CI, 0.63 to 0.78]).6, Among the study populations, the proportion of CVD events prevented (i.e., the relative risk reduction) was similar across age, sex, race/ethnicity, lipid level, and other risk factor categories.6 Among trials that stratified participants according to a baseline global cardiovascular risk score, similar relative risk estimates were observed among those classified at a higher vs. lower CVD event risk.10,23. MeSH Based on moderate-quality evidence from RCTs, maximally tolerated statin therapy is recommended for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL (4.92 mmol per L) or greater. This series is coordinated by Michael J. Arnold, MD, contributing editor. B recommendation. This medicine comes with a patient information leaflet. High-quality evidence from RCTs recommends that patients 40 to 75 years of age without diabetes who are at intermediate risk with LDL-C levels of 70 to 189 mg per dL (1.81 to 4.90 mmol per L) should be treated with a moderate-intensity statin. What Does It Matter If You Have High Cholesterol? Instead of LDL targets, the guidelines identify groups of people who are at high risk of having a heart attack or stroke. We suggested that only for absolute contraindication or adverse effects of statins should we adjust LLT, it is better to maintain the dosage of statins after target level achieved. The USPSTF has made other recommendations relevant to the prevention of CVD in adults, including aspirin use for the prevention of CVD, screening for coronary heart disease using electrocardiography, use of nontraditional risk factors in CVD risk assessment, screening for high blood pressure, screening for abnormal blood glucose levels and type 2 diabetes mellitus, interventions for tobacco smoking cessation, behavioral counseling to promote a healthful diet and physical activity for CVD prevention in adults, and screening for and management of obesity in adults. Although statin use may be beneficial for the primary prevention of CVD events in some adults with a 10-year CVD event risk of less than 10%, the likelihood of benefit is smaller, because of a lower probability of disease and uncertainty in individual risk prediction. Ask your doctor or pharmacist for advice if you're unsure how much to take. Qjm. The optimal time of day for statin administration: a review of current information highlighted below and resubmit the form. Unauthorized use of these marks is strictly prohibited. AHA/ASA Stroke Secondary Prevention Guideline: Key Points Other risk factors, such as family history of premature coronary artery disease, have not been demonstrated to improve risk prediction in a clinically meaningful way.15. All rights reserved. A 30% or greater reduction in LDL-C levels is recommended, and in high-risk patients a 50% or greater reduction is recommended. Statin Use for the Primary Prevention of Cardiovascular Disease in Medical uses Statins are usually used to lower blood cholesterol levels and reduce risk for illnesses related to atherosclerosis, with a varying degree of effect depending on underlying risk factors and history of cardiovascular disease. When cholesterol levels are measured, nonfasting samples have equivalent accuracy and should be used routinely. Bookshelf A low-dose statin was found to be more effective at reducing low-density lipoprotein cholesterol (LDL-C) than 6 commonly used dietary supplements marketed for cholesterol health . These effects translate to additional cardiovascular benefits, including: These effects can also help reduce blood pressure, particularly in people with prehypertension who are not yet on blood pressure medication.. Taking a lower dosage of statins may mean incorporating another cholesterol lowering drug into the treatment plan. persistent muscle pain muscle pain or weakness that does not go away when this drug is stopped abdominal pain fever dark-colored urine Warning for liver disease and alcohol misuse: People with. It appears that the expectation of the side effect makes it more likely to occur. Cholesterol levels are stable for up to 10 years, with most change between measurements due to testing variability.13 There is no need to repeatedly measure cholesterol more than once a decade for risk calculations. The USPSTF systematically searched for evidence on the effect of screening for dyslipidemia in adults aged 21 to 39 years. One hundred and three consecutive stroke patients follow up at out-patient clinic (44 women, 59 men) were recruited. Dyslipidemia Management for Cardiovascular Disease Prevention: Guidelines from the VA/DoD, USPSTF Recommendations for the Management of Dyslipidemia for Cardiovascular Risk Reduction, http://tools.acc.org/ASCVD-Risk-Estimator-Plus, Suggest against routinely ordering a lipid panel more frequently than every 10 years in patients not taking statin therapy, Suggest against routine use of coronary artery calcium testing, Consider measuring coronary artery calcium in adults 40 to 75 years of age without diabetes mellitus and with an LDL-C level of 70 to 189 mg per dL (1.81 to 4.90 mmol per L) at a 10-year risk of 7.5% to 19.9% if a decision about statin therapy is uncertain, Offer a moderate-dose statin in patients with a 12% 10-year cardiovascular risk or an LDL-C level of > 190 mg per dL (4.92 mmol per dL) or who have diabetes; suggest shared decision-making if the 10-year cardiovascular risk is between 6% and 12%, Offer maximally tolerated statin therapy for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL, Suggest against maximizing the statin dose in patients taking moderate-dose statins because of the risks of higher-dose statins and the lack of evidence proving added cardiovascular benefits, Reasonable to prescribe high-intensity statin therapy in adults with diabetes who have multiple risk factors, with the aim to reduce LDL-C levels by 50%, Insufficient evidence to recommend for or against using ezetimibe (Zetia) with or without statins, Reasonable to add a nonstatin drug (ezetimibe or bile acid sequestrant) to a moderate-intensity statin in intermediate-risk adults who would benefit from more aggressive LDL-C lowering and in whom high-intensity statins are advisable but not acceptable or tolerated, Recommend against offering PCSK9 inhibitors because of unknown long-term safety, inconclusive evidence for benefit, and high cost, Consider adding PCSK9 inhibitor in patients 40 to 75 years of age with a baseline LDL-C level of 220 mg per dL (5.70 mmol per L) and who achieve an on-treatment LDL-C level of 130 mg per dL (3.37 mmol per L) while receiving maximally tolerated statin and ezetimibe therapy, Insufficient evidence to recommend for or against icosapent ethyl in patients taking statin therapy with persistently elevated fasting triglyceride levels, None (guideline published before REDUCE-IT trial of icosapent ethyl), Recommend using at least a moderate-dose statin, Initiate or continue moderate-intensity statin therapy in patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience statin-associated adverse effects, with the aim of achieving a 30% to 49% reduction in LDL-C levels, Offer high-dose statins and add ezetimibe or PCSK9 inhibitors to moderate- or high-dose statins for higher-risk patients who are willing to intensify treatment; maximize statin dose and add ezetimibe before adding PCSK9 inhibitors, Initiate or continue high-intensity statin therapy in patients who are 75 years who have clinical ASCVD, with the aim of achieving a 50% reduction in LDL-C levels, Offer icosapent ethyl for patients taking statin therapy with persistently elevated fasting triglyceride levels > 150 mg per dL (1.69 mmol per L) to reduce cardiovascular morbidity and mortality, Suggest against the use of omega-3 fatty acids as a dietary supplement to reduce cardiovascular disease risk, For patients who cannot tolerate taking a statin, offer a washout period followed by a rechallenge with the same or different statin or lower dose; if that is ineffective, offer a trial of intermittent (nondaily) dosing, Reassess and rechallenge for patients with statin-associated adverse effects that are not severe to achieve a maximal LDL-C lowering by modified dosing regimen, an alternate statin, or in combination with nonstatin therapy, Suggest against the routine monitoring of lipid levels in patients taking statins, Assess adherence and percentage response to LDL-Clowering medications and lifestyle changes with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated every 3 to 12 months as needed. As previously noted, available RCTs evaluating statins for the prevention of CVD events largely used low and moderate doses. Managing statin muscle pain - Harvard Health An alternative to statins may help reduce deaths from heart disease . A healthy lifestyle reduces ASCVD risk at all ages and can reduce the development of risk factors in younger patients. Children younger than 8 years of ageUse and dose must be determined by your doctor. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. To provide you with the most relevant and helpful information, and understand which Moderate-quality evidence from nonrandomized studies recommends estimating the 10-year ASCVD risk of a first fatal or nonfatal myocardial infarction or stroke by using the race and sex-specific pooled cohort equations. Atorvastatin: a medicine to treat high blood cholestesterol - NHS Unfortunately, the evidence is lacking in this age group. . Saved Stories. PMC Lowering cholesterol isn't the only benefit associated with statins. The USPSTF concludes with moderate certainty that initiating use of low- to moderate-dose statins for the prevention of CVD events and mortality in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 7.5% to 10% has a small net benefit. The usual dose for adults is between 10mg and 80mg a day. By Richard N. Fogoros, MD It is important to note that the calculated 10-year CVD event risk derived from the ACC/AHA risk calculator is heavily influenced by age. the unsubscribe link in the e-mail. No, Recommendations based on patient-oriented outcomes? See permissionsforcopyrightquestions and/or permission requests. The USPSTF has made several other recommendations relevant to the prevention of CVD in adults (see the Other Approaches to Prevention section). Editors Note: Similar to the 2013 ACC/AHA cholesterol guideline, this guideline has some utility for family physicians but is limited by several recommendations that will be challenging to implement and lack patient-oriented evidence. An AHA science advisory in 2017 said omega-3 fish oil supplements may slightly lower the risk of dying after heart failure or a recent heart attack, but they do not prevent heart disease. JAMA. They work by blocking a substance your body needs to make cholesterol. Given the imprecision in risk estimates, eliciting patients values and preferences regarding the potential benefits and harms of statins and other lipid-lowering agents remains essential to treatment decisions.Kenny Lin, MD, MPH, AFP Deputy Editor, Guideline source: American College of Cardiology/American Heart Association, Systematic literature search described? The most common include: Statins can also cause an elevation in liver enzymes in one of every 100 users. Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine. The majority (> 80%) use a statin alone.29 The survey did not distinguish between the use of cholesterol-lowering medications for the purposes of primary vs. secondary prevention, so it is not possible to determine how many of these persons have had a previous heart attack or ischemic stroke. Why? Careers. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. It encourages the expanded use of CAC scoring to guide the decision to start statin therapy, even though no studies have shown that risk stratification based on CAC score reduces cardiovascular morbidity or mortality more than traditional risk factors alone. For heterozygous familial hypercholesterolemia: Children 10 to 17 years of age5 to 20 mg per day. No trial data evaluated statin use among persons in this age group without CVD risk factors; thus, the evidence is insufficient to know whether statin use provides them the same or less benefit than in similarly aged adults with CVD risk factors. Based on high-quality RCTs, fasting lipid measurement should be repeated four to 12 weeks after starting the statin or making a dose adjustment to assess adherence and response to LDL-Clowering medications and lifestyle changes. Your doctor may adjust your dose as needed. Kellick KA, Bottorff M, Toth PP. The USPSTF found adequate evidence that the harms of low- to moderate-dose statin use in adults aged 40 to 75 years are small. Initiate use of low- to moderate-dose statins. In addition to this medicine, your doctor may change your diet to one that is low in fat, sugar, and cholesterol. These can include: muscle aches Rosuvastatin (Oral Route) Proper Use - Mayo Clinic Cardiovascular disease risk calculators, such as the pooled cohort equations (http://tools.acc.org/ASCVD-Risk-Estimator-Plus), have reasonable accuracy to guide clinical decision-making.3 Other than the conventional risk factors included in calculators, no additional factors improve risk estimation.3 Coronary artery calcium scoring has not been demonstrated to improve patient outcomes, even in intermediate-risk populations where treatment decisions are less certain.3,4, Strong evidence supports moderate-dose statins as the best therapy in primary prevention for patients at elevated risk, with relative risk reductions in cardiovascular events and mortality of 20% to 30% over five years.5 Moderate-dose statins are well tolerated, with minimal risk of diabetes mellitus or rhabdomyolysis.6 Limited study of high-dose statins for primary prevention shows similar cardiovascular benefits as moderate-dose statins, with increased risks of diabetes and statin intolerance.7 Ezetimibe (Zetia) has not been studied as monotherapy and, in combination with a statin, is not better than statins alone.8 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been shown to reduce risk better than placebo in primary prevention.9 Icosapent ethyl was not beneficial in the primary prevention subgroup of a randomized trial.10 The ACC/AHA guidelines also recommend moderate-dose statins, although high-dose statins and additional medications are suggested for certain conditions despite lack of evidence of superior outcomes.2 These suggestions are extrapolated from a goal of at least 50% low-density lipoprotein cholesterol (LDL-C) reduction, which is supported by observational data but not by direct clinical trials.2, Because primary prevention trials did not use risk calculators for inclusion criteria, treatment thresholds are somewhat arbitrary. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. For example, 41% of men and 27% of women aged 60 to 69 years without a history of CVD will be found to have a calculated 10-year CVD event risk of 10% or greater.16 Many older adults, particularly those aged 65 to 75 years, may meet the recommended risk threshold for treatment with statins in spite of the absence of dyslipidemia, diabetes, hypertension, or smoking. Vegetarian and vegan diets linked to lower levels of cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology. Carefully follow your doctor's orders about any special diet. Statin drugs lower cholesterol levels by inhibiting a liver enzyme, known as HMG Co-A reductase, which is key to cholesterol synthesis. Potential Harms.
